Skip to main content
. 2021 May 31;13(6):817. doi: 10.3390/pharmaceutics13060817

Figure 2.

Figure 2

In vivo dose-responsiveness study of tL-5G3. (a,b) The hepatic expression levels of miRNA-122-targeted or non-targeted mRNAs in mice (6-week-old male C57Bl6/J, n = 3–4) after 7 days of injection at a dosage of 75–3 nmol/kg of tL-5G3 and 25–9 nmol/kg of tinyCtr-5G3. (c,d) Their corresponding miRNA-122 expression levels and serum cholesterol levels, respectively. (e) Serum total cholesterol levels of the tinyCtr-5G3-treated arms. ** p < 0.01 and * p < 0.05 (vs. saline).